Abstract
Introduction:
The treatment of migraine is an underserved, underdiagnosed market with great growth potential. Despite the current dominance of triptan therapies, the upcoming entrance of new formulations and new applications of existing treatments, as well as the introduction of new therapeutic agents, will likely substantially alter the market.
Get the Answers You Need to Shape Your Strategy:
No signifi cantly new treatment for migraine has been launched since the advent of the 5-HT1 agonists, also known as triptans. Are there other potentially effective treatments on the horizon? What effect could new treatments have on the current market? Two areas of migraine treatment exist: prophylactic, which seeks to prevent the occurrence of migraine, and abortive, which treats the symptoms of migraine after they have begun. What room for growth does each of these treatment areas contain? Which area holds the most growth potential? What are some of the roadblocks to new treatment development? GlaxoSmithKline' s fi rst patent on Imitrex is scheduled to expire in July 2007. What effect will this have on the market? What products are poised to enter the market? What is GSK doing to protect its current market dominance? What can other companies do to take advantage of this imminent patent expiration?
Scope:
- Migraine background: Symptoms, triggers, etiology, and possible implicated neurotransmitters.
- Patient population: Size and makeup of migraine patient populations worldwide.
- Current approaches to migraine treatment: Current migraine treatments; their mechanisms of action; characteristics such as onset of action and duration of action, effi cacy, and side effects; and the factors infl uencing treatment choice.
- Current market: Current migraine market, both domestic and international.
- Emerging migraine therapies: New formulations of and delivery systems for existing drugs and the development of new agents. Timetable for testing and market entry for each emerging therapy.
- Market outlook: The near future for markets in the United States, Europe, and Japan; factors that will affect the market; and possible future scenarios.
Companies Mentioned in this Spectrum Report:
- Abbott
- Alexza
- Almirall
- Applied Pharma Research
- Aradigm
- Ariston
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Cobalt Pharmaceuticals
- Dr. Reddy' s Laboratories
- Eisai
- Elan
- Endo Pharmaceuticals
- GlaxoSmithKline
- Johnson & Johnson
- Kyorin
- Menarini
- Merck
- Minster Pharmaceutical
- Mylan
- NovaDel
- Novartis
- Organon
- Pierre Fabre
- Pfi zer
- Pozen
- ProEthic
- Ranbaxy
- Roche
- Schwarz Pharma
- Spectrum Pharmaceuticals
- Torrey Pines Therapeutics
- Valeant Pharmaceuticals
- Vernalis
- Winston
- Wyeth
- Zogenix
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- An Overview of Migraine
- Etiology and Pathophysiology
- Symptoms and Triggers
- Epidemiology
- Current Treatment
- Abortive Treatments
- Triptans
- Ergot Derivatives
- Prophylactic Therapies
- Beta Blockers
- NSAIDS
- Antiepileptic Agents
- Antidepressants
- 5-HT Antagonists
- Current Market
- Emerging Agents
- Abortive Therapies
- Pozen and GSK' s Trexima
- NovaDel' s Sublingual Sumatriptan
- Zogenix' s Subcutaneous Sumatriptan
- Alexza' s Prochlorperazine
- ProEthic' s Diclofenac
- Pozen' s Lornoxicam
- GlaxoSmithKline' s 274150
- GlaxoSmithKline' s 705498
- Boehringer Ingelheim' s Olcegepant
- Prophylactic Therapies
- Ariston' s AST-726
- Minster Pharmaceutical' s Tonabersat
- TorreyPines Therapeutics' Tezampanel
- Eisai' s E-2007
- Winston' s Zucapsaicin
- Market Outlook
- New Opportunities in the Migraine Market
- Generic Threats
- Outlook to 2010
Tables
- 1. Neurotransmitters and Biochemicals Implicated in Migraine Attacks
- 2. Leading Branded Prescription Treatments for Migraine, 2005
- 3. Products in Clinical Development for the Treatment of Migraine
Figures
- 1. Select Precipitating (Triggers) Factors Associated with Migraine
- 2. Time Course of Migraine Symptom Intensity and Recommended Treatments
- 3. Worldwide Triptan Market, 2005
